Suche
Ihre Suche nach "%2A" ergab 75 Treffer
- Zeuzem, S; Arora, S; Bacon, B et al.
- PEGYLATED INTERFERON-LAMBDA (PEGIFN-lambda) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFN alpha-2A IN HCV PATIENTS (G1/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12
- JOURNAL OF HEPATOLOGY. Bd. 54. 2011 S. S538-S539
- Altrichter, S.; Staubach, P.; Pasha, M. et al.
- Efficacy and safety data of AK002, an anti-siglec-8 monoclonal antibody, in patients with multiple forms of uncontrolled chronic urticaria (CU): Results from an open-label phase 2a study
- ALLERGY. Bd. 74. 2019 S. 120-120
- Sprinzl, M.; Grambihler, A.; Teuber, G. et al.
- Addition of pegylated interferon alfa-2a to an ongoing nucleos(t) ide treatment accelerates decrease of HBs-antigen levels in patients with chronic hepatitis B: Results from the PADD-ON study
- JOURNAL OF HEPATOLOGY. Bd. 68. 2018 S. S108-S109
- Jacobson, Ira M.; Asselah, Tarik; Ferenci, Peter et al.
- STARTVerso3: A randomized, double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection
- HEPATOLOGY. Bd. 58. 2013 S. 742A-743A
- Werfel, T.; Lynch, V; Asher, A. et al.
- A phase 2a proof of concept clinical trial to evaluate ZPL-3893787 (ZPL-389), a potent, oral histamine H-4 receptor antagonist for the treatment of moderate to severe atopic dermatitis (AD) in adults
- ALLERGY. Bd. 71. 2016 S. 95-95
- Yoshida, Eric M.; Asselah, Tarik; Moreno, Christophe et al.
- Subgroup analyses and baseline predictors of response with faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection: A pooled analysis of STARTVerso1 and 2
- HEPATOLOGY. Bd. 58. 2013 S. 751A-752A
- Moog, Gero; Mauss, Stefan; Hueppe, Dietrich et al.
- Efficacy of Boceprevir Based Triple Therapy in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) Under Real Life Conditions in Treatment Experienced Patients Infected With Chronic Hepatitis C, Genotype 1: The PAN Study
- GASTROENTEROLOGY. Bd. 144. H. 5. 2013 S. S982-S982
- Pol, S; Berg, T; Bonacini, M et al.
- VIROLOGICAL RESPONSE AND SAFETY OF BI 201335 PROTEASE INHIBITOR, PEGINTERFERON ALFA 2A AND RIBAVIRIN TREATMENT OF HCV GENOTYPE-1 PATIENTS WITH COMPENSATED LIVER CIRRHOSIS AND NON-RESPONSE TO PREVIOUS PEGINTERFERON RIBAVIRIN
- HEPATOLOGY. Bd. 50. H. 6. 2009 S. 10A-11A
- Moog, Gero; Mauss, Stefan; Hueppe, Dietrich et al.
- Triple Therapy Under Real Life Conditions: Telaprevir (TVR) and Boceprevir (BOC) in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) in Treatment Experienced Patients Infected With Chronic Hepatitis C, Genotype 1. the PAN Study
- GASTROENTEROLOGY. Bd. 144. H. 5. 2013 S. S980-S980
- Jensen, Donald M.; Asselah, Tarik; Dieterich, Douglas T. et al.
- A pooled analysis of two randomized, double-blind placebo-controlled Phase III trials (STARTVerso1&2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection
- HEPATOLOGY. Bd. 58. 2013 S. 734A-735A